Voglibose in Combination of Three Hypoglycemic Agents in the Treatment of Type 2 Diabetes Mellitus
Journal Title: Міжнародний ендокринологічний журнал - Year 2016, Vol 6, Issue 78
Abstract
The aim of the study — clinical and metabolic rationale for the selection of the third hypoglycemic agent to enhance the effectiveness of treatment in patients with diabetes mellitus (DM) type 2, assessment of the impact of the therapy intensification due to the addition of voglibose on carbohydrate metabolism parameters, which have not reached target levels during the combination therapy with metformin and glimepiride. Materials and methods. We observed 45 patients with DM type 2, who have not reached the targets of carbohydrate metabolism under the influence of previous treatments (metformin and glimepiride). After the initial clinical examination, patients were divided into two groups. In the first group (n = 30), wе added to the treatment the drug voglibose (Voxid, production of Kusum Pharm Ltd, Ukraine) 0.2 mg before breakfast, lunch and dinner for 12 weeks. Results. After 12 weeks of treatment, the level of glycated hemoglobin (НbА1с) in the first group decreased by 1.5 [1.1; 1.9] % (p < 0.05), in the second group — by 0.1 [0.09; 0.6] % (p > 0.05). 80 % of patients achieved target levels of glycemia. The first group of patients showed a significant increase in HOMA-β index by 24.9 %, as well as a reduction of insulin resistance (HOMA-IR) by 31.5 %. After 12 weeks of therapy, there was a statistically significant decrease in body weight by 2.1 kg in the first group of patients and no response in patients of the second group. Safety has been proveв in terms of the functional state of the liver and kidneys in this therapy. Conclusions. Adding voglibose for intensification of therapy in patients with type 2 DM, who had previously received metformin and glimepiride, has led to a significant improvement in carbohydrate metabolism (decrease in HbA1c by 1.5 %). Better control of carbohydrate metabolism during the combination therapy with metformin, glimepiride, and voglibose is accompanied by an increase of functional activity of pancreatic β-cells, a decrease in insulin resistance in the background of weight loss.
Authors and Affiliations
V. I. Pankivn, I. V. Cherniavska
Keywords
Related Articles
- EP ID EP177848
- DOI 10.22141/2224-0721.6.78.2016.81858
- Views 42
- Downloads 0
Pharmacological profile of the Normocycle phytocomposition in the treatment of hormonal imbalances in women
The article presents pharmacodynamic characteristics of the components of the Normocycle® phytocomposition (Organosyn pharmaceutical company), the main active components of which are extracts of Symplocos racemosa, Aspa...
The State of Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes Mellitus
Background. The problem of impairment of bone mineral density (BMD) in postmenopausal women is relevant due to a high risk of osteoporotic fractures, especially against the comorbid pathology. The aim of the study was to...
Serum tumor markers in thyroid diseases
The article highlights the role of serum tumor markers in the diagnosis and treatment of thyroid diseases, primarily various forms of cancer. Clinical indications for the prescription and current recommendations for eval...
Structural and Functional Indexes of Cardiovascular System and Kidneys Against Insulin Resistance in Patients with Type 2 Diabetes Mellitus and Obesity
The article deals with the results of study of structural and functional indexes of the cardiovascular system and kidneys, pancreatic β-cells function, severity of insulin resistance in patients with type 2 diabetes mell...
Prevalence of Оsteoporosis and Low Bone Mineral Density in Ukrainian Women with Obesity and Metabolic Syndrome
Objective: to determine the incidence of osteoporosis and low bone mineral density (BMD) in Ukrainian women with obesity and metabolic syndrome. Materials and methods. The study involved 1,605 persons, whose mean age was...